NASDAQ:ATHX Athersys (ATHX) Stock Forecast, Price & News $0.95 -0.04 (-4.35%) (As of 02:54 PM ET) Add Compare Share Share Today's Range$0.89▼$0.9950-Day Range$0.77▼$1.4552-Week Range$0.50▼$10.50Volume62,513 shsAverage Volume228,790 shsMarket Capitalization$17.47 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Athersys MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside478.9% Upside$5.50 Price TargetShort InterestHealthy4.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector859th out of 1,006 stocksPharmaceutical Preparations Industry430th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingAthersys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Athersys has a forecasted upside of 478.9% from its current price of $0.95.Amount of Analyst CoverageAthersys has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.86% of the float of Athersys has been sold short.Short Interest Ratio / Days to CoverAthersys has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Athersys has recently decreased by 4.44%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAthersys does not currently pay a dividend.Dividend GrowthAthersys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHX. Previous Next 2.0 News and Social Media Coverage News SentimentAthersys has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Athersys this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ATHX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Athersys to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athersys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.40% of the stock of Athersys is held by insiders.Percentage Held by InstitutionsOnly 20.23% of the stock of Athersys is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Athersys is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athersys is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Athersys (NASDAQ:ATHX) StockAthersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.Read More Receive ATHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHX Stock News HeadlinesMay 23, 2023 | msn.comAthersys restructures debt with supplier, prioritizing multi-stem for stroke treatmentMay 23, 2023 | finance.yahoo.comAthersys Restructures Debt with SupplierMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 22, 2023 | americanbankingnews.comAthersys (NASDAQ:ATHX) Upgraded by StockNews.com to HoldMay 18, 2023 | bizjournals.comAthersys cuts quarterly loss as restructuring takes holdMay 18, 2023 | finance.yahoo.comAthersys Reports First Quarter 2023 Financial Results and Business HighlightsMay 16, 2023 | americanbankingnews.comAthersys, Inc. (NASDAQ:ATHX) Short Interest UpdateMay 16, 2023 | americanbankingnews.comAthersys (NASDAQ:ATHX) Downgraded by StockNews.com to SellMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 8, 2023 | finance.yahoo.comAthersys to Participate in Three Upcoming ConferencesMay 4, 2023 | americanbankingnews.comAthersys (NASDAQ:ATHX) Stock Rating Upgraded by StockNews.comMay 1, 2023 | finance.yahoo.comAthersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care ConferenceApril 21, 2023 | finance.yahoo.comAthersys to Participate in The American Society for Neural Therapy and Repair Annual ConferenceApril 19, 2023 | finance.yahoo.comAthersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private PlacementApril 18, 2023 | finance.yahoo.comAthersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private PlacementApril 12, 2023 | businesswire.comAthersys to Host Business Update Conference Call on April 20 thApril 10, 2023 | finance.yahoo.comAthersys to Host Business Update Conference Call on April 20thMarch 31, 2023 | finance.yahoo.comAthersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsMarch 31, 2023 | finance.yahoo.comAthersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsMarch 22, 2023 | finance.yahoo.comAthersys Announces Successful Type B Meeting with the FDAFebruary 14, 2023 | finance.yahoo.comAthersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol DiscussionFebruary 2, 2023 | finance.yahoo.comAthersys to Host Business Update Conference Call on February 14thJanuary 30, 2023 | finance.yahoo.comAthersys to Participate in International Stroke Conference and BioProcess InternationalJanuary 11, 2023 | finance.yahoo.comAthersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in JanuaryJanuary 9, 2023 | finance.yahoo.comAthersys Provides MultiStem Clinical UpdateJanuary 4, 2023 | thestreet.comAthersys (ATHX) Stock Plummets to 52-Week Low as Stroke Therapy Fails Mid-Stage TrialJanuary 2, 2023 | thestreet.comHere’s Why Athersys (ATHX) Stock is Jumping TodaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHX Company Calendar Last Earnings3/31/2023Today5/31/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATHX CUSIPN/A CIK1368148 Webwww.athersys.com Phone(216) 431-9900Fax216-361-9495Employees104Year Founded1995Price Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$5.50 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+478.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,530,000.00 Net Margins-1,362.14% Pretax Margin-2,408.99% Return on EquityN/A Return on Assets-193.59% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.20 Sales & Book Value Annual Sales$5.32 million Price / Sales3.29 Cash FlowN/A Price / Cash FlowN/A Book Value($1.68) per share Price / Book-0.57Miscellaneous Outstanding Shares18,450,000Free Float16,714,000Market Cap$17.53 million OptionableOptionable Beta-0.71 Social Links Key ExecutivesDaniel A. CamardoChief Executive Officer, Secretary, Director & CAOMaia A. HansenChief Operating OfficerKasey RosadoChief Financial OfficerRakesh RamachandranHead-Information Technology & CommunicationsManal MorsyExecutive VP & Head-Global Regulatory AffairsKey CompetitorsLucy Scientific DiscoveryNASDAQ:LSDIMoleculin BiotechNASDAQ:MBRXEdesa BiotechNASDAQ:EDSAHumanigenNASDAQ:HGENPaxMedicaNASDAQ:PXMDView All CompetitorsInstitutional OwnershipState Street CorpBought 13,200 shares on 5/16/2023Ownership: 0.230%Susquehanna International Group LLPBought 18,700 shares on 5/16/2023Ownership: 0.000%CIBC Asset Management IncBought 36,376 shares on 5/12/2023Ownership: 0.197%Group One Trading L.P.Sold 33,100 shares on 5/12/2023Ownership: 0.000%Simplicity Solutions LLCBought 31,395 shares on 4/27/2023Ownership: 0.170%View All Institutional Transactions ATHX Stock - Frequently Asked Questions Should I buy or sell Athersys stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATHX shares. View ATHX analyst ratings or view top-rated stocks. What is Athersys' stock price forecast for 2023? 1 brokers have issued twelve-month target prices for Athersys' shares. Their ATHX share price forecasts range from $5.50 to $5.50. On average, they predict the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 478.9% from the stock's current price. View analysts price targets for ATHX or view top-rated stocks among Wall Street analysts. How have ATHX shares performed in 2023? Athersys' stock was trading at $0.84 at the start of the year. Since then, ATHX stock has increased by 13.1% and is now trading at $0.95. View the best growth stocks for 2023 here. When is Athersys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ATHX earnings forecast. How were Athersys' earnings last quarter? Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings results on Friday, March, 31st. The biopharmaceutical company reported ($0.83) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.03 million for the quarter. When did Athersys' stock split? Athersys's stock reverse split before market open on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is William (B.J.) Lehmann's approval rating as Athersys' CEO? 1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend. What other stocks do shareholders of Athersys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA). What is Athersys' stock symbol? Athersys trades on the NASDAQ under the ticker symbol "ATHX." Who are Athersys' major shareholders? Athersys' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vahanian & Associates Financial Planning Inc. (4.44%), State Street Corp (0.23%), CIBC Asset Management Inc (0.20%), Group One Trading L.P. (0.00%), Simplicity Solutions LLC (0.17%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Daniel A Camardo, Ismail Kola, Ivor Macleod, John J Harrington, John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr. View institutional ownership trends. How do I buy shares of Athersys? Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Athersys' stock price today? One share of ATHX stock can currently be purchased for approximately $0.95. How much money does Athersys make? Athersys (NASDAQ:ATHX) has a market capitalization of $17.53 million and generates $5.32 million in revenue each year. The biopharmaceutical company earns $-72,530,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. How many employees does Athersys have? The company employs 104 workers across the globe. How can I contact Athersys? Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for the company is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495. This page (NASDAQ:ATHX) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.